Welcome to our dedicated page for Rain Enhancement news (Ticker: RAIN), a resource for investors and traders seeking the latest updates and insights on Rain Enhancement stock.
Rain Oncology Inc. (NasdaqGS: RAIN) is a clinical-stage biotechnology company developing precision therapies targeting specific cancer drivers. This news hub provides investors and researchers with timely updates on the company's progress in oncology innovation, including its lead candidate milademetan and strategic initiatives.
Access authoritative updates on clinical trial developments, regulatory milestones, and corporate announcements. The resource consolidates essential information about RAIN's therapeutic pipeline, financial position, and partnership activities – critical data points for evaluating the company's trajectory in precision medicine.
Key coverage areas include progress in Phase 3 MANTRA trials for liposarcoma, updates on tumor-agnostic basket studies, and analysis of strategic merger plans with Pathos AI. All content maintains rigorous standards for accuracy and clarity, serving both professional investors and those monitoring advancements in cancer treatment.
Bookmark this page for direct access to verified Rain Oncology announcements and objective reporting on developments impacting the company's scientific and financial progress.
Rain Oncology Inc. (NasdaqGS: RAIN) announced that CEO Avanish Vellanki will present a corporate overview at the Oppenheimer 33rd Annual Healthcare Conference on March 13, 2023, at 11:20 a.m. ET, virtually. Rain is focused on developing precision oncology therapeutics, particularly its lead candidate, milademetan, which inhibits the MDM2-p53 complex to reactivate p53. The presentation will be available via live webcast, with a replay accessible later on the Rain website. Rain is also advancing a preclinical program aimed at inducing synthetic lethality in cancer cells through RAD52 inhibition.
Rain Oncology Inc. (NasdaqGS: RAIN) announced it will report its fourth quarter and full-year financial results for 2022 on March 9, 2023. This will include highlights of recent progress, primarily focusing on its lead candidate, milademetan, an oral small molecule designed to inhibit the MDM2-p53 complex and reactivate p53. A conference call and webcast will be hosted at 2:00 pm PT (5:00 pm ET) to discuss these results. Interested parties can access the call via dial-in or the provided webcast link. Rain is committed to precision oncology, selecting patients based on genetic profiling to enhance therapeutic effectiveness.
Rain Oncology Inc. (NasdaqGS: RAIN) has announced that CEO Avanish Vellanki will participate in a fireside chat at the Citi Virtual Oncology Leadership Summit on February 21, 2023, at 12:00 p.m. ET. The event will be held virtually, and interested parties can access a live webcast here. A replay will be available on Rain's website after the event. Rain specializes in precision oncology, focusing on therapies like milademetan, which targets the p53-MDM2 complex.
Rain Oncology Inc. (NasdaqGS: RAIN) announced that CEO Avanish Vellanki will participate in a fireside chat at the Guggenheim Healthcare Talks Oncology Day Conference on February 8, 2023, at 9:35 a.m. ET, in New York, NY. The discussion will provide insights into the company's leading product candidate, milademetan, an oral small molecule inhibitor targeting the p53-MDM2 complex, which reactivates p53. A live webcast of the event can be accessed here. A replay will be available on the company's website.
Rain Oncology Inc. (RAIN) has published a peer-reviewed article detailing Phase 1 clinical data of its drug, milademetan, a p53-MDM2 complex inhibitor, in advanced dedifferentiated liposarcoma (DD LPS). The study indicates that intermittent dosing (260 mg qd, 3/14 days) demonstrates favorable safety and tolerability, leading to a median progression-free survival (mPFS) of 7.4 months for patients on this schedule. The company is preparing for the registrational Phase 3 MANTRA trial and has reported a significant reduction in severe drug-related thrombocytopenia compared to continuous dosing. Milademetan has received Orphan Drug Designation from the FDA.
Rain Therapeutics Inc. will change its name to Rain Oncology Inc. effective December 30, 2022, to better represent its focus on precision oncology for cancer patients. CEO Avanish Vellanki emphasized the company's dedication to developing new strategies in this field. The name change will not affect current stockholders, and the ticker symbol RAIN will remain unchanged. Rain is working on its lead product candidate, milademetan, an oral MDM2-p53 complex inhibitor, and aims to utilize a tumor-agnostic approach in its oncology therapies.
Rain Therapeutics Inc. (NasdaqGS: RAIN) announced its participation in the J.P. Morgan 41st Annual Health Care Conference from January 9-12, 2023, in San Francisco, CA. CEO Avanish Vellanki will present on January 11, 2023, at 9:00 a.m. PT, offering a corporate overview. Rain is a late-stage biotechnology firm focusing on precision oncology therapeutics, notably its lead candidate, milademetan, an oral inhibitor of the MDM2-p53 complex, designed to reactivate p53.
The company utilizes a tumor-agnostic strategy to identify patients likely to benefit from its therapies.
Rain Therapeutics Inc. (NasdaqGS: RAIN) has announced a poster presentation at the 2022 San Antonio Breast Cancer Symposium, scheduled for December 6-10, 2022. The presentation will focus on genetic alterations in breast cancer linked to MDM2 dependency and sensitivity to milademetan, an oral inhibitor targeting the MDM2-p53 complex. The poster session is set for December 9, 2022, at the Henry B. Gonzalez Convention Center. Rain aims to use precision oncology to select patients based on genetic profiles rather than tumor histology.
Rain Therapeutics (NasdaqGS: RAIN) announced its participation in Piper Sandler’s 34th Annual Healthcare Conference from November 29 to December 1, 2022, in New York. CEO Avanish Vellanki will join a fireside chat on December 1 at 1:30 p.m. ET. The event will be accessible via webcast. Rain Therapeutics specializes in precision oncology and is developing milademetan, an oral inhibitor targeting the MDM2-p53 complex to reactivate p53. The company also has a preclinical program aimed at inducing synthetic lethality in cancer cells through RAD52 inhibition.
Rain Therapeutics Inc. (NASDAQ: RAIN) announced an oral presentation on its lead product candidate, milademetan, at the Connective Tissue Oncology Society Annual Meeting in Vancouver, Canada, from November 16-19, 2022. The presentation, titled Sustained disease control with MDM2 inhibitor milademetan in patients with advanced dedifferentiated liposarcoma, will be given by Dr. Mrinal M. Gounder on November 17, 2022. Rain Therapeutics focuses on precision oncology, developing therapies targeting oncogenic drivers, alongside a preclinical program inhibiting RAD52.
FAQ
What is the current stock price of Rain Enhancement (RAIN)?
What is the market cap of Rain Enhancement (RAIN)?
